Contribution of Immune Activation to the Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection, Clinical Microbiology Reviews, vol.14, issue.4, pp.753-777, 2001. ,
DOI : 10.1128/CMR.14.4.753-777.2001
Cortisol patterns are associated with T cell activation in HIV.PLoS One Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis, AIDS, vol.823, issue.725, pp.634291059-1067, 2009. ,
Microbial translocation is a cause of systemic immune activation in chronic HIV infection, Nature Medicine, vol.174, issue.12, pp.20061365-71 ,
DOI : 10.1038/nm1511
ICONA Foundation Study Group Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count, AIDS Jul, vol.1725, issue.11, pp.1385-94, 2011. ,
Human Cytomegalovirus Induces Systemic Immune Activation Characterized by a Type 1 Cytokine Signature, The Journal of Infectious Diseases, vol.202, issue.5, pp.690-699, 2010. ,
DOI : 10.1086/655472
Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus???Infected Patients<subtitle>A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4</subtitle><alt-title>Antiretroviral Drugs, Risk of MI, and HIV</alt-title>, Archives of Internal Medicine, vol.170, issue.14, pp.1228-1266, 2010. ,
DOI : 10.1001/archinternmed.2010.197
Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review, PLoS ONE, vol.13, issue.8, p.59551, 2013. ,
DOI : 10.1371/journal.pone.0059551.s001
HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte Activation, Clinical Infectious Diseases, vol.55, issue.1, pp.126-162, 2012. ,
DOI : 10.1093/cid/cis406
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.7, pp.2506-2512, 2007. ,
DOI : 10.1210/jc.2006-2190
Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV-1 Infection?, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.30, issue.5, pp.471-477, 2002. ,
DOI : 10.1097/00126334-200208150-00002
Cumulative exposure to stimulants and immune function outcomes among HIV-positive and HIV-negative men in the Multicenter AIDS Cohort Study, International Journal of STD & AIDS, vol.96, issue.8 ,
DOI : 10.1258/ijsa.2012.011322
Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems, AIDS, vol.28, issue.7, 2014. ,
DOI : 10.1097/QAD.0000000000000184
Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, Euro surveill, vol.13, 2004. ,
HIV and Aging, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.60, issue.37 1, pp.1-18, 2012. ,
DOI : 10.1097/QAI.0b013e31825a3668
Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d'experts. Rapport 2013, 2013. ,
HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals; for the French Hospital Database on HIV (FHDH)?ANRS CO4a, pp.600-606 ,
Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease, Arch Intern Med, vol.171, issue.8, pp.737-780, 2011. ,
T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient Study, Clinical Infectious Diseases, vol.51, issue.4, pp.435-447, 2010. ,
DOI : 10.1086/655144
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study, HIV Medicine, vol.2, issue.2, pp.218-248, 2006. ,
DOI : 10.1086/378131
General cardiovascular risk profile for use in primary care: the Framingham Heart study, Circulation, vol.117, pp.743-753, 2008. ,
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.Circulation, pp.1603-1611, 2004. ,
Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals, AIDS, vol.27, issue.3, pp.381-390, 2013. ,
DOI : 10.1097/QAD.0b013e32835abcc9
Should HIV-infected patients be screened for silent myocardial ischaemia using gated myocardial perfusion SPECT?, European Journal of Nuclear Medicine and Molecular Imaging, vol.17, issue.10, pp.2013271-2013280 ,
DOI : 10.1007/s00259-012-2262-1
Diagnostic et Traitement de l'ostéoporose, HAS. Juillet, 2006. ,
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults, AIDS, vol.23, issue.8, pp.1021-1024, 2009. ,
DOI : 10.1097/QAD.0b013e3283292195
URL : https://hal.archives-ouvertes.fr/inserm-00374705
Osteoporosis and fractures in HIV/hepatitis C virus coinfection, AIDS, vol.28, issue.14, 2014. ,
DOI : 10.1097/QAD.0000000000000363
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents, AIDS, vol.26, issue.7, pp.825-856, 2012. ,
DOI : 10.1097/QAD.0b013e32835192ae
Risk factors for decreased bone density and effects of HIV on bone in the elderly, Osteoporosis International, vol.90, issue.7, pp.913-921, 2007. ,
DOI : 10.1007/s00198-007-0524-8
Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.12, pp.4522-4528, 2007. ,
DOI : 10.1210/jc.2007-1660
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors, AIDS, vol.22, issue.3, pp.395-402, 2008. ,
DOI : 10.1097/QAD.0b013e3282f423dd
URL : https://hal.archives-ouvertes.fr/inserm-00186715
Actualisation 2012 des recommandations françaises du traitement médicamenteux de l'ostéoporose post ménopausique. Revue du rhumatisme, 2012. ,
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary, Canadian Medical Association Journal, vol.182, issue.17, pp.1864-1873, 2010. ,
DOI : 10.1503/cmaj.100771
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals, Ann. N.Y. Sci, pp.1281-106, 2013. ,
Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy, AIDS, vol.16, issue.16, pp.183-93, 2002. ,
DOI : 10.1097/00002030-200211080-00011
Metabolic disorders and chronic viral disease: The case of HIV and HCV, Diabetes & Metabolism, vol.35, issue.1, pp.1-11, 2009. ,
DOI : 10.1016/j.diabet.2008.08.003
Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors, Hepatology, vol.48, issue.Suppl 1, pp.71-78, 2010. ,
DOI : 10.1002/hep.23619
Nonalcoholic Fatty Liver Disease in HIV???Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors, Clinical Infectious Diseases, vol.47, issue.2, pp.250-256, 2008. ,
DOI : 10.1086/589294
Antiretroviral drugs and liver injury, AIDS, vol.22, issue.1, pp.1-13, 2008. ,
DOI : 10.1097/QAD.0b013e3282f0e2fd
Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus infection: assessment using transient elastometry and the role of HCV genotype 3, BMC Infect Dis Clin Infect Dis, vol.1042, issue.70, pp.1032-1039, 2006. ,
Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome, Journal of Viral Hepatitis, vol.10, issue.0, pp.165-172, 2008. ,
DOI : 10.1016/S0168-8278(98)80198-0
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis, Journal of Hepatology, vol.51, issue.2, pp.371-379, 2009. ,
DOI : 10.1016/j.jhep.2009.03.019
Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection, The American Journal of Gastroenterology, vol.9, issue.6, pp.1346-53, 2010. ,
DOI : 10.1038/ajg.2009.746
Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients, HIV Medicine, vol.143, issue.6, pp.375-378, 2005. ,
DOI : 10.1097/00002030-200303280-00010
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index, Journal of Hepatology, vol.43, issue.1, pp.78-84, 2005. ,
DOI : 10.1016/j.jhep.2005.02.025
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, vol.41, issue.6, pp.1317-1342, 2006. ,
DOI : 10.1002/hep.21178
FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest, Hepatology, vol.13, issue.1, pp.32-38, 2007. ,
DOI : 10.1002/hep.21669
The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis, AIDS, vol.22, issue.14, pp.1799-1807, 2008. ,
DOI : 10.1097/QAD.0b013e32830e0152
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis, BMC Public Health, vol.22, issue.14, p.234, 2012. ,
DOI : 10.1097/QAD.0b013e32830e0152
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients, AIDS, vol.24, issue.11, pp.1667-1678, 2010. ,
DOI : 10.1097/QAD.0b013e328339fe53
Association of tenofovir exposure with kidney disease risk in HIV infection, AIDS, vol.26, issue.7, pp.867-875, 2012. ,
DOI : 10.1097/QAD.0b013e328351f68f
Role of traditional Risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-01101114
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care, AIDS, vol.26, issue.15, 2012. ,
DOI : 10.1097/QAD.0b013e328357f5ed
Effect of tenofovir on renal glomerular and tubular function, AIDS, vol.21, issue.11, pp.1483-1485, 2007. ,
DOI : 10.1097/QAD.0b013e328216f15b
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir, AIDS, vol.26, issue.5, pp.567-575, 2012. ,
DOI : 10.1097/QAD.0b013e32834f337c
Incidence of renal toxicity in HIV-infected, antiretroviral-na??ve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir, Scandinavian Journal of Infectious Diseases, vol.25, issue.2, pp.147-154, 2013. ,
DOI : 10.1097/QAD.0b013e32834bba87
Chronic Renal failure in HIV-Infected Patients: Incidence and risk factors (ANRS CO3 Aquitaine Cohort, France), th Conférence on Retroviruses and Opportunistics Infections (CROI), 2010. ,
Proteinuria among HIV-Infected HAART recipients in the multicenters AIDS cohort study (MACS). 4th conference on HIV Pathogenesis and treatment and prevention Sydney, 2007. ,
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, The Journal of Pathology, vol.89, issue.1, pp.12-21, 1999. ,
DOI : 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
Study of human papillomavirus infection in patients with anal squamous carcinoma, Diseases of the Colon & Rectum, vol.39, issue.1, pp.37-46, 1996. ,
DOI : 10.1007/BF02048266
On the etiology of anal squamous carcinoma, Dan Med Bull, vol.49, issue.3, pp.194-209, 2002. ,
Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings, AIDS, vol.24, issue.3, pp.373-382, 2010. ,
DOI : 10.1097/QAD.0b013e328333ab8e
Updated research nosology for HIV-associated neurocognitive disorders, Neurology, vol.69, issue.18, pp.1789-99, 2007. ,
DOI : 10.1212/01.WNL.0000287431.88658.8b
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia, AIDS, vol.24, issue.9, pp.1243-50, 2010. ,
DOI : 10.1097/QAD.0b013e3283354a7b
Pathogenesis of HIV in the Central Nervous System, Current HIV/AIDS Reports, vol.4, issue.5, pp.54-60, 2011. ,
DOI : 10.1007/s11904-010-0070-4
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy, AIDS, vol.25, issue.14, pp.1747-51, 2011. ,
DOI : 10.1097/QAD.0b013e32834a40cd
Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men, Neurology, vol.73, issue.16, pp.1292-1299, 2009. ,
DOI : 10.1212/WNL.0b013e3181bd10e7
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons, Neurology, 2010. ,
Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care, HIV Medicine, vol.49, issue.Suppl 3, pp.99-107, 2013. ,
DOI : 10.1111/j.1468-1293.2012.01043.x
Pathogenesis of Hepatitis C Virus Coinfection in the Brains of Patients Infected with HIV, (105) HAS. Prise en charge d'un épisode dépressif isolé de l'adulte en ambulatoire, pp.361-70, 2002. ,
DOI : 10.1086/519285
Managing Depression in Medical Outpatients, New England Journal of Medicine, vol.343, issue.26, pp.1942-50, 2000. ,
DOI : 10.1056/NEJM200012283432607
Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United StatesArch Gen Psychiatry, 2001. ,
Projections of Global Mortality and Burden of Disease from 2002 to 2030, PLoS Medicine, vol.52, issue.11, p.442, 2006. ,
DOI : 10.1371/journal.pmed.0030442.st007
Coronary Heart Disease in HIV-Infected Individuals, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.33, issue.4, p.506, 2003. ,
DOI : 10.1097/00126334-200308010-00012
Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study, Clinical Infectious Diseases, vol.44, issue.12, pp.1625-1631, 2007. ,
DOI : 10.1086/518285
Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis, HIV Medicine, vol.126, pp.453-468, 2012. ,
DOI : 10.1111/j.1468-1293.2012.00996.x
Turchi MD Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIVinfected persons, ScientificWorldJournal, vol.2013, p.969281, 2013. ,
D study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study ,
Cardiovascular Risk Estimation in 2012: Lessons Learned and Applicability to the HIV Population, Journal of Infectious Diseases, vol.205, issue.suppl 3, pp.362-369 ,
DOI : 10.1093/infdis/jis196
CISAI study group. Decreasing cardiovascular risk in HIV infection between, AIDS. Feb, vol.2028, issue.4, pp.609-621, 2005. ,
Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID).5 th IAS conference on HIV pathogenesis and treatment. Cape Town, 2009. ,
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population, AIDS, vol.24, issue.8, pp.1228-1230, 2010. ,
DOI : 10.1097/QAD.0b013e328339192f
Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti???HIV Drugs (D:A:D) Study, The Journal of Infectious Diseases, vol.201, issue.3, pp.318-330, 2010. ,
DOI : 10.1086/649897
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons, AIDS, vol.25, issue.10, pp.1289-1298, 2011. ,
DOI : 10.1097/QAD.0b013e328347fa16
Abacavir use and cardiovascular disease events, AIDS, vol.25, issue.16, pp.1993-2004, 2011. ,
DOI : 10.1097/QAD.0b013e328349c6ee
Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study, AIDS Care, vol.83, issue.8, pp.929-967, 2011. ,
DOI : 10.1152/japplphysiol.01035.2007
Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects, Atherosclerosis, vol.208, issue.1, pp.222-229, 2010. ,
DOI : 10.1016/j.atherosclerosis.2009.06.011
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Alimentary Pharmacology & Therapeutics, vol.11, issue.6 Pt 2, pp.274-285, 2011. ,
DOI : 10.1111/j.1365-2036.2011.04724.x
Metabolic Syndrome Predicts All-Cause Mortality in Persons with Human Immunodeficiency Virus, AIDS Patient Care and STDs, vol.27, issue.5, pp.266-71, 2013. ,
DOI : 10.1089/apc.2012.0402
A Comparison of Factors Associated With Prevalent Diabetes Mellitus Among HIV-Infected Antiretroviral-Naive Individuals Versus Individuals in the National Health and Nutritional Examination Survey Cohort, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.45, issue.1, pp.66-71, 2007. ,
DOI : 10.1097/QAI.0b013e318031d7e3
Veterans Aging Cohort StudyAIDS, HIV infection and the risk of diabetes mellitus, pp.1227-1261, 2009. ,
Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment, AIDS, vol.26, issue.3, pp.303-317, 2012. ,
DOI : 10.1097/QAD.0b013e32834e8776
URL : https://hal.archives-ouvertes.fr/hal-00875222
The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy, Journal of Biological Chemistry, vol.275, issue.27, pp.20251-20255, 2000. ,
DOI : 10.1074/jbc.C000228200
Association of Clinical and Therapeutic Factors with Incident Dyslipidemia in a Cohort of Human Immunodeficiency Virus???Infected and Non-Infected Adults: 1994???2011, ) (186) HAS. Dépistage de l'infection par le VIH en France-stratégies et dispositif de dépistage, p.417, 2009. ,
DOI : 10.1089/met.2013.0017
Etudes de Freins à la prise en charge par le médecin généraliste des patients vivant avec le VIH. 2014. (188) Lavoix A. Etat des lieux de la prise en charge en médecine générale des patients infectés par le VIH en Mayenne en 2012, 2013. ,
Immune activation in HIV-infected aging women on antiretrovirals--implications for age-associated comorbidities: a cross-sectional pilot study Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort, J Acquir Immune Defic Syndr, vol.8, issue.5, p.63804, 2010. ,
Sereti I; INSIGHT Study Group. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death, J Infect Dis, vol.2034, issue.11, pp.1637-1683, 2011. ,
Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection, PLoS Medicine, vol.180, issue.10, pp.51496-1508, 2008. ,
DOI : 10.1371/journal.pmed.0050203.sd002
Subclinical Atherosclerosis and Markers of Immune Activation in HIV-Infected Children and Adolescents, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.65, issue.1, pp.42-51, 2014. ,
DOI : 10.1097/QAI.0b013e3182a9466a
Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy, Diabetes Care, vol.33, issue.10, pp.2244-2253, 2010. ,
DOI : 10.2337/dc10-0633
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients, Current Opinion in HIV and AIDS, vol.9, issue.1, pp.80-86 ,
DOI : 10.1097/COH.0000000000000019
Predicting risk of cancer during HIV infection, AIDS, vol.27, issue.9, pp.1433-1474, 2013. ,
DOI : 10.1097/QAD.0b013e32835f6b0c
URL : https://hal.archives-ouvertes.fr/hal-01101192
The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression, Journal of Infection, vol.66, issue.1, pp.201357-66 ,
DOI : 10.1016/j.jinf.2012.09.013
Predictors of CD4:CD8 Ratio Normalization and Its Effect on Health Outcomes in the Era of Combination Antiretroviral Therapy, PLoS ONE, vol.1, issue.10, p.77665, 2013. ,
DOI : 10.1371/journal.pone.0077665.t003
HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality, PLoS Pathogens, vol.185, issue.5, p.1004078, 2014. ,
DOI : 10.1371/journal.ppat.1004078.s011
Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatmentEpub ahead of print] 4. Infection à papillomavirus 5. Herpès 6. Autres infections sexuellement transmissibles : ????????.????. d'inutilité,Diminution des facultés de concentration et de prise de décision, Idées suicidaires ou tentative de suicide Nb FDR fibrose Age>50; IMC>30;ATCD Diabete=OUI syndrome métabolique, J Infect Dis.Oui, 2014. ,
TG>1,7;1;0); TTaille>102 And Sexe=Un Homme" And TTaille?0 ,TTaille>92 And Sexe=Une FemmeOr Chol HDL<1,3 And Sexe= "Une Femme, Lipodystrophie="Hypertrophie abdominale", type NrTI1="AZT" Or Type NrTI2="AZT" Or type INTI3="AZT" Or Type NrTI1="D4T" Or Type NrTI2="D4T" Or type INTI3= ,
Oui";ATCD fract=, Oui, vol.1 ,
HVC Chronique active"; Prise Cortisone plus 3 mois="Oui, p.7 ,
Un Homme"; TAsyst>130;1;0) ,
Chol HDL<1 And Sexe=Un Homme";(Chol HDL < 1,3 And Sexe=Une Femme";Glycémie>5,6;1;0);TTaille?80 And Sexe=, Une Femme, vol.7 ,
Supérieur à 400 copies";Hépatite C="HVC Chronique active";Type NrTI1="TFV" Or Type NrTI2="TFV" Or type IP="Atazanavir";1;0); ATCD calcul=, p.10000 ,